Kunming Pharmaceutical Group Secretary Zhang Mengxun resigns, with an annual salary of 1.33 million yuan; CFO Sun Zhiqiang takes over.

Rui Finance Liu Zhiping On March 31, Yunnan Baiyao Group (SH600422) announced that, due to personal reasons, Zhang Mengxun has applied to resign from her positions as the company’s Vice President, Secretary to the Board of Directors, Chief Legal Counsel, and Chief Compliance Officer. After stepping down, Zhang Mengxun will no longer hold any position within the company.

In accordance with the company’s development and the needs of production and business operations management, the company’s board of directors has appointed Sun Zhiqiang as the Secretary to the Board of Directors, with a term from the date this board meeting’s resolution is approved until the expiration of the 11th Board of Directors.

Sun Zhiqiang, male, born in 1980, graduated from Zhongnan University of Economics and Law with a major in Accounting (Certified Public Accountant) and holds a bachelor’s degree in Management. He previously served as Area Financial Management Manager at Shenzhen Sanjiu Pharmaceutical Trading Co., Ltd., Regional Financial Management Director and Marketing Business Financial Director at China Resources Sanjiu Pharmaceutical Co., Ltd., Assistant General Manager and Financial Director at Kunming China Resources Shenghuo Pharmaceutical Co., Ltd., and Assistant General Manager at the Financial Management Center of China Resources Sanjiu Pharmaceutical Co., Ltd. He is currently the Financial Director, Financial Controller, and Secretary to the Board of Directors at Yunnan Baiyao Group Co., Ltd.

Zhang Mengxun, born in 1978, holds a PhD in law. She has previously worked as a practicing lawyer at Shanghai Lizhao Law Firm and Shanghai Yishi Law Firm, served as Assistant General Manager in the Legal Affairs Department and Deputy General Manager of the Board Office, and also as General Manager and Securities Affairs Representative at Shanghai Industrial Development Co., Ltd. She has served as Vice President, Secretary to the Board of Directors, Chief Legal Counsel, and Chief Compliance Officer at Yunnan Baiyao Group Co., Ltd.

In 2025, the compensation for Sun Zhiqiang and Zhang Mengxun is 1.3761 million yuan and 1.327 million yuan, respectively.

Yunnan Baiyao Group was established on December 14, 1995. The legal representative is Zhong Jiang. The registered capital is 757 million yuan. Its main business includes drug research and development, manufacturing, sales, pharmaceutical distribution, and the health and big health industry. The company’s main products include treatments for cardiovascular and cerebrovascular diseases, orthopedic series, antimalarial drugs, gynecology, digestive system, and others, as well as wholesale and retail of pharmaceuticals and medical devices.

In 2025, Yunnan Baiyao Group’s operating revenue is approximately 6.575 billion yuan, a year-on-year decrease of 21.74%; net profit attributable to shareholders of listed companies is approximately 350 million yuan, a decrease of 46% year-on-year; and net profit after deducting non-recurring gains and losses is 107 million yuan, a decrease of 74.45% year-on-year.

Related company: Yunnan Baiyao Group sh600422